News

Maxygen said the agreement would allow the company to use Avimer technology allowing it to develop unique products which have the potential to be important drug targets. Avimer

With support from the University of Wisconsin-Milwaukee, the researchers found that jellyfish-based compound aequorin has yielded promising results. The scientists subjected brain cells to the “lab” equivalent of

Provenge is an investigational product that may represent the first in a new class of active cellular immunotherapies that are uniquely designed to stimulate a patient’s own immune

Results also demonstrated a low rate of side effects in treatment naive patients with genotype-1 HCV infection after 24 weeks of treatment. Earlier in the year the trial

The phase IIIb trial showed that the patch could offer individualized control over a child’s ADHD symptoms, allowing parents and physicians to better manage the potential for late-day

The study examined Vertex’s investigational hepatitis C virus protease inhibitor, telaprevir in combination with pegylated interferon (peg-IFN) with or without ribavirin. The hepatitis C virus was suppressed in

The work, which was directed by Dr Yun-Sil Lee from the Korea Institute of Radiological and Medical Sciences in Seoul, Korea, found that targeted overexpression of heat shock

Both a 750mg dose and 375mg dose of naproxcinod were evaluated in the study. Both were shown to be superior to placebo on all three efficacy endpoints of

The company reported third quarter 2006 net earnings from continuing operations of $338 million, compared to $964 million, for the same period in 2005. Bristol-Myers Squibb said the